Reviews
Barriers to Molecular Biomarker Testing in LMIC Neuro-Oncology Clinical Trials: A Scoping Review
Rafique & SharifJPMA
The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System relies heavily on molecular diagnostics for accurate tumor characterization, prognostic assessment, and clinical trial stratification. However, inequitable access to advanced diagnostic infrastructure in low- and middle-income countries (LMICs) presents substantial real-world obstacles to standard-of-care diagnostics and trial recruitment. A scoping review incorporating 17 studies examined the infrastructural, technical, and operational challenges surrounding molecular testing in resource-restricted neuro-oncology settings.
Severe deficits in advanced diagnostic modalities—specifically next-generation sequencing (NGS), DNA methylation profiling, and fluorescence in situ hybridization (FISH)—routinely preclude WHO CNS5-compliant diagnoses. Consequently, central nervous system tumors in these settings frequently receive "not otherwise specified" (NOS) classifications, directly disqualifying eligible patients from enrollment in molecularly stratified clinical trials. Beyond platform availability, clinical trial recruitment is compromised by significant diagnostic delays, a shortage of specialized neuropathology expertise, and non-standardized biomarker reporting protocols.
Systemic physician-level barriers further impede trial participation. Survey data from 223 LMIC clinicians revealed that the absence of investigator-initiated funding and insufficient personal time allocation serve as the primary institutional constraints hindering research engagement. While minimally invasive diagnostics like cerebrospinal fluid (CSF) cell-free DNA (cfDNA) demonstrated clinical promise—achieving an 82.5% circulating tumor DNA (ctDNA) detection rate in glioma cases—widespread implementation remains restricted by procedural invasiveness and prohibitive sequencing costs.
Addressing these diagnostic disparities requires structured, collaborative interventions. Evidence-based strategies highlighted in the literature include the establishment of virtual molecular tumor boards, international capacity-building collaborations, and modified regional consensus guidelines. Furthermore, trial sponsors and cooperative groups must adopt multi-tiered biomarker strategies in future trial designs that adjust inclusion criteria to align with regional laboratory capabilities.
Key Takeaways
- Inadequate access to next-generation sequencing, DNA methylation profiling, and fluorescence in situ hybridization prevents WHO CNS5-compliant classification, yielding "not otherwise specified" diagnoses that restrict patient eligibility for molecularly stratified neuro-oncology trials.
- In a survey of 223 clinicians in low- and middle-income countries, lack of investigator-initiated funding and inadequate personal time allocation were identified as the primary systemic barriers to trial engagement.
- Cerebrospinal fluid cell-free DNA liquid biopsy achieved an 82.5% ctDNA detection rate in glioma cases, though clinical utility remains limited by sequencing costs and procedural invasiveness.
